A new treatment option, Datroway (datopotamab deruxtecan or Dato-DXd), is now available for people with non-small cell lung ...

Datroway (datopotamab deruxtecan) is the first TROP2-directed therapy approved for advanced lung cancer in the U.S.

Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.

AstraZeneca PLC (NASDAQ:AZN) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company announced ...

The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a ...

DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non ...

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

The FDA has blessed AstraZeneca and Daiichi Sankyo’s Datroway to treat patients with locally advanced or metastatic epidermal ...

DATROWAY ® has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR- mutated non-small cell lung cancer who have received prior EGFR- directed ...

The US Food and Drug Administration (FDA) has approved Datroway (datopotamab deruxtecan or Dato-DXd) to treat adults with ...

A potential $4 billion licensing deal with Vor Bio triggered a slide in RemeGen's stock price. Otsuka obtained a BCMAXCD3 ...